Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.

Image source: Getty Images

Coles Group Ltd (ASX: COL)

According to a note out of Citi, analysts have retained their buy rating and $19.00 price target on this supermarket giant's shares. Citi has been visiting stores to get a better idea of how the big two supermarket operators are performing with their respective strategies. It believes that Coles' pricing strategy is resonating more with consumers and will result in stronger sales growth during the fourth quarter of FY 2024. This is based on its belief that Coles' strategy is being executed better and has a stronger value perception. And while Citi rates both supermarket giants as buys, its preference at this point is Coles. The Coles share price ended the week at $16.42.

Pro Medicus Limited (ASX: PME)

A note out of Goldman Sachs reveals that its analysts have reiterated their buy rating on this health imaging technology company's shares with an improved price target of $136.00. This follows news that Pro Medicus has won five new contracts with a minimum contract value of $45 million. Goldman highlights that this brings the company's minimum total contract value (TCV) for new sales this financial year to $245 million. And there's still potential for more contract wins given its sizeable sales pipeline. Goldman believes this supports its view that the company's Visage 7 software is an industry-leading solution and that the company is the incumbent technology leader in radiology and well-placed to take market share. The Pro Medicus share price was fetching $120.12 at Friday's close.

Qantas Airways Limited (ASX: QAN)

Another note out of Goldman Sachs reveals that its analysts have retained their buy rating and $8.05 price target on this airline operator's shares. Goldman believes that the market is severely undervaluing Qantas' shares. It suspects that this could be due to investors pricing in a trade off between investment (fleet and customer) and capital returns (dividends and buybacks). However, the broker believes that Qantas can return significant capital to shareholders and invest in its fleet while still maintaining a strong balance sheet. As a result, its analysts see the Flying Kangaroo's cheap valuation as a buying opportunity. It is also worth noting that Goldman is expecting the Qantas dividend to return in 2025. The Qantas share price ended the week at $6.15.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has positions in and has recommended Coles Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A white EV car and an electric vehicle pump with green highlighted swirls representing ASX lithium shares
Broker Notes

Here's what brokers tip for PLS shares over the next 12 months

PLS shares ripped 275% in FY26. Here are 6 new 12-month share price targets from the experts.

Read more »

Happy friends holding shopping bags in a shopping mall.
Broker Notes

Buy, hold, sell: Myer, Centuria Office REIT, Viva Energy shares

Analysts reveal their ratings and 12-month share price targets.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Broker Notes

Morgans names 3 ASX shares to buy now

The broker has named these shares as buys following their results.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city.
Broker Notes

5 ASX 200 broker buy ratings

One of these buy-rated stocks could potentially rise as much as 55%.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Broker Notes

Why this broker thinks REA Group shares are a sell right now

There could be more downside for this ASX 200 stock.

Read more »

A woman reaches her arms to the sky as a plane flies overhead at sunset.
Broker Notes

2 ASX travel stocks to buy and one to sell

These airline stocks are defying fuel price impacts and are set to lift off.

Read more »

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: Orora, Virgin Australia, and ResMed shares

Ord Minnett has given its verdict on these shares.

Read more »